Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2231 to 2240 of 2588 total matches.

Comparison Table: Some Oral/Transdermal Opioid Analgesics (online only)

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022  (Issue 1665)
have been reported, particularly after >1 month of use Hyperalgesia, worsening pain that cannot be overcome ...
View the Comparison Table: Some Oral/Transdermal Opioid Analgesics
Med Lett Drugs Ther. 2022 Dec 12;64(1665):e199-202 |  Show IntroductionHide Introduction

Fat Substitutes

   
The Medical Letter on Drugs and Therapeutics • Jun 15, 1990  (Issue 820)
. The Medical Letter, Inc. Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB SITE: http://www.medletter.com ...
Two new substitutes for fat will soon be available in supermarkets in the USA, not directly, but incorporated into low-fat foods. Simplesse (NutraSweet) has already been approved for use by the US Food and Drug Administration (FDA) and is commercially available in some areas, but only in an ice-cream-like product called Simple Pleasures. Trailblazer (Kraft General Foods) is expected to be approved soon.
Med Lett Drugs Ther. 1990 Jun 15;32(820):57 |  Show IntroductionHide Introduction

Screening for Melanoma

   
The Medical Letter on Drugs and Therapeutics • Sep 05, 2011  (Issue 1372)
for melanoma and other skin cancers.1 HIGH-RISK GROUPS — Patients with red hair, fair skin, numerous freckles ...
In the absence of randomized studies demonstrating an impact on mortality, the US Preventive Services Task Force (USPSTF) has found the evidence insufficient to recommend a routine whole-body examination for melanoma and other skin cancers.
Med Lett Drugs Ther. 2011 Sep 5;53(1372):72 |  Show IntroductionHide Introduction

Do Calcium Supplements Increase the Risk of Myocardial Infarction?

   
The Medical Letter on Drugs and Therapeutics • Oct 17, 2011  (Issue 1375)
in women with an inadequate dietary intake of calcium.1 The safety of calcium supplements has recently ...
Supplemental calcium is recommended for prevention of postmenopausal osteoporosis in women with an inadequate dietary intake of calcium. The safety of calcium supplements has recently been questioned; patients may ask if they should continue to take them. The source of this concern was the publication of 2 meta-analyses in the British Medical Journal.
Med Lett Drugs Ther. 2011 Oct 17;53(1375):83 |  Show IntroductionHide Introduction

Sitagliptin and Simvastatin (Juvisync)

   
The Medical Letter on Drugs and Therapeutics • Nov 14, 2011  (Issue 1377)
hemoglobin (A1C) and fasting blood glucose levels.1 DPP-4 inhibitors are generally used as alternatives ...
The FDA has approved Juvisync (Merck), a fixed-dose combination of the antihyperglycemic DPP-4 inhibitor sitagliptin (Januvia) and the HMG-CoA reductase inhibitor simvastatin (Zocor, and others).
Med Lett Drugs Ther. 2011 Nov 14;53(1377):89 |  Show IntroductionHide Introduction

An Imaging Agent for Amyloid

   
The Medical Letter on Drugs and Therapeutics • Jul 09, 2012  (Issue 1394)
. IMAGING — Florbetapir binds to fibrillary -amyloid found in neuritic plaques.1,2 After IV injection ...
The FDA has approved florbetapir F18 (flor bay´ ta pir; Amyvid – Lilly), an intravenous radioactive diagnostic agent used with positron emission tomography (PET) scans, to estimate β-amyloid neuritic plaque density in adults being evaluated for Alzheimer's disease (AD) or other causes of cognitive decline.
Med Lett Drugs Ther. 2012 Jul 9;54(1394):54-5 |  Show IntroductionHide Introduction

In Brief: Warning Against Use of Valproate for Migraine Prevention During Pregnancy

   
The Medical Letter on Drugs and Therapeutics • Jun 10, 2013  (Issue 1418)
altogether, if possible, in women of childbearing age.1 VALPROATE — Valproic acid and divalproex sodium ...
The FDA is advising health care professionals not to prescribe valproate sodium (Depacon), valproic acid (Depakene, Stavzor, and generics) or divalproex sodium (Depakote, Depakote ER, and generics) for migraine prevention in pregnant women because a recently published study showed that IQ scores are decreased in children of mothers who took these drugs during pregnancy. The FDA recommends avoiding valproate altogether, if possible, in women of childbearing age.1VALPROATE — Valproic acid and divalproex sodium dissociate to valproate in the GI tract. Valproate is considered the drug of choice...
Med Lett Drugs Ther. 2013 Jun 10;55(1418):45 |  Show IntroductionHide Introduction

Rethinking Warfarin for Atrial Fibrillation

   
The Medical Letter on Drugs and Therapeutics • Sep 30, 2013  (Issue 1426)
competing with warfarin (Coumadin, and others) for the oral anticoagulant market.1 NEW ORAL ANTICOAGULANTS ...
Full-page newspaper advertisements and a series of television commercials have urged patients with atrial fibrillation to "rethink warfarin" in favor of Eliquis (apixaban – Bristol-Myers Squibb). Apixaban is the latest of 3 new oral anticoagulants now competing with warfarin (Coumadin, and others) for the oral anticoagulant market.
Med Lett Drugs Ther. 2013 Sep 30;55(1426):77 |  Show IntroductionHide Introduction

In Brief: Suspension of Johnson & Johnson COVID-19 Vaccine Lifted (online only)

   
The Medical Letter on Drugs and Therapeutics • May 17, 2021  (Issue 1624)
million doses of the single-dose vaccine had been administered in the US at the time of the review.1-4 ...
On April 23, 2021, on advice from the Advisory Committee on Immunization Practices (ACIP), the FDA and CDC recommended that use of the Johnson & Johnson adenovirus-based COVID-19 vaccine resume despite its association with development of thrombosis with thrombocytopenia syndrome (TTS). Administration of the vaccine had been paused on April 13 because of 6 reports of TTS, but after completing a data review that identified a further 9 cases associated with the formulation, the agencies concluded that the benefits of the vaccine outweighed its risks. About 7.98 million doses of the...
Med Lett Drugs Ther. 2021 May 17;63(1624):e1 |  Show IntroductionHide Introduction

Drugs of Choice for Cancer

   
Treatment Guidelines from The Medical Letter • Mar 01, 2003  (Issue 7)
. (ISSN 1541-2784) Vol. 1 (Issue 7) March 2003 Published by The Medical Letter, Inc. 1000 Main ...
The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. In some cases, such as elderly patients or those with many co-morbid illnesses, the regimen of choice might not be suitable. For many of the cancers listed, surgery and/or radiation therapy may be the treatment of choice or may also be part of the management. Anticancer...
Treat Guidel Med Lett. 2003 Mar;1(7):41-52 |  Show IntroductionHide Introduction